

# Ronald Simon

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7256537/ronald-simon-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

401  
papers

17,421  
citations

65  
h-index

120  
g-index

422  
ext. papers

19,942  
ext. citations

6.3  
avg, IF

5.8  
L-index

#	Paper	IF	Citations
401	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , <b>2015</b> , 163, 1011-25	56.2	1713
400	Molecular classification of cutaneous malignant melanoma by gene expression profiling. <i>Nature</i> , <b>2000</b> , 406, 536-40	50.4	1647
399	Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. <i>Nature Genetics</i> , <b>2007</b> , 39, 655-60	36.3	291
398	Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. <i>British Journal of Cancer</i> , <b>2006</b> , 94, 128-35	8.7	291
397	Prognostic relevance of gene amplifications and coamplifications in breast cancer. <i>Cancer Research</i> , <b>2004</b> , 64, 8534-40	10.1	277
396	Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. <i>Cancer Cell</i> , <b>2013</b> , 23, 159-70	24.3	259
395	Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. <i>Journal of Pathology</i> , <b>1999</b> , 187, 396-402	9.4	257
394	Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. <i>American Journal of Pathology</i> , <b>2012</b> , 181, 401-12	5.8	256
393	Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 1141-6	9.7	248
392	ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5878-88	12.9	225
391	Prevalence of KIT expression in human tumors. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 4514-22	2.2	196
390	High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2004</b> , 86, 207-13	4.4	195
389	Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. <i>Journal of Pathology</i> , <b>1999</b> , 189, 521-6	9.4	190
388	High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. <i>Prostate</i> , <b>2011</b> , 71, 281-8	4.2	179
387	Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. <i>Cell Reports</i> , <b>2014</b> , 8, 798-806	10.6	177
386	HER-2 amplification is highly homogenous in gastric cancer. <i>Human Pathology</i> , <b>2009</b> , 40, 769-77	3.7	176
385	The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 97, 275-83	4.4	176

384	CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. <i>Cancer Research</i> , <b>2013</b> , 73, 2795-805	10.1	169
383	Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. <i>European Urology</i> , <b>2016</b> , 69, 592-598	10.2	167
382	Clinical significance of p53 alterations in surgically treated prostate cancers. <i>Modern Pathology</i> , <b>2008</b> , 21, 1371-8	9.8	165
381	Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. <i>Modern Pathology</i> , <b>2007</b> , 20, 120-9	9.8	154
380	Tissue microarrays in drug discovery. <i>Nature Reviews Drug Discovery</i> , <b>2003</b> , 2, 962-72	64.1	150
379	Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. <i>Journal of Pathology</i> , <b>2001</b> , 194, 165-70	9.4	137
378	Impaired gastric acidification negatively affects calcium homeostasis and bone mass. <i>Nature Medicine</i> , <b>2009</b> , 15, 674-81	50.5	133
377	SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 4257-67	15.9	131
376	Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 6579-84	12.9	128
375	Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. <i>Oncogene</i> , <b>2002</b> , 21, 2476-83	9.2	126
374	Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. <i>Laboratory Investigation</i> , <b>2004</b> , 84, 465-78	5.9	125
373	E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. <i>Oncogene</i> , <b>2004</b> , 23, 5616-23	9.2	124
372	Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. <i>Cancer Research</i> , <b>2006</b> , 66, 2328-37	10.1	123
371	Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. <i>Modern Pathology</i> , <b>2013</b> , 26, 975-83	9.8	121
370	Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. <i>Oncogene</i> , <b>2007</b> , 26, 5680-91	9.2	118
369	TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF- $\beta$ signaling. <i>BMC Cancer</i> , <b>2011</b> , 11, 507	4.8	117
368	Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. <i>Journal of Pathology</i> , <b>1998</b> , 185, 345-51	9.4	114
367	Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1553-60	12.9	113

366	Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. <i>Journal of Pathology</i> , <b>2013</b> , 231, 130-41	9.4	112
365	High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. <i>Cancer Research</i> , <b>2001</b> , 61, 4514-9	10.1	109
364	Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. <i>Cancer Discovery</i> , <b>2012</b> , 2, 1024-35	24.4	107
363	The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 2919-33	12.9	106
362	Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. <i>Prostate</i> , <b>2009</b> , 69, 976-81	4.2	100
361	BAZZA (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. <i>Nature Genetics</i> , <b>2015</b> , 47, 22-30	36.3	99
360	Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 56-64	12.9	98
359	Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. <i>Cancer Research</i> , <b>2011</b> , 71, 1362-73	10.1	98
358	Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. <i>International Journal of Cancer</i> , <b>2006</b> , 118, 2190-4	7.5	96
357	HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. <i>Journal of Clinical Pathology</i> , <b>2007</b> , 60, 768-72	3.9	90
356	Tissue microarrays. <i>BioTechniques</i> , <b>2004</b> , 36, 98-105	2.5	89
355	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. <i>Cancer Cell</i> , <b>2018</b> , 34, 996-1011.e8	24.3	89
354	Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. <i>Experimental Hematology</i> , <b>2002</b> , 30, 1365-72	3.1	86
353	Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 1369-80	7.5	85
352	Influence of slide aging on results of translational research studies using immunohistochemistry. <i>Modern Pathology</i> , <b>2004</b> , 17, 1414-20	9.8	84
351	HER-2 and TOP2A coamplification in urinary bladder cancer. <i>International Journal of Cancer</i> , <b>2003</b> , 107, 764-72	7.5	84
350	High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 1273-9	7.5	83
349	Comparative genomic hybridization (CGH) analysis of neuroblastomas--an important methodological approach in paediatric tumour pathology. <i>Journal of Pathology</i> , <b>1997</b> , 181, 394-400	9.4	83

348	KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 178-83	12.9	83
347	Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 4415-29	12.9	83
346	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. <i>BMC Gastroenterology</i> , <b>2015</b> , 15, 7	3	82
345	Expression and prognostic relevance of annexin A3 in prostate cancer. <i>European Urology</i> , <b>2008</b> , 54, 1314-23	12.2	82
344	Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. <i>Cancer Research</i> , <b>2004</b> , 64, 1632-8	10.1	78
343	High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. <i>Journal of Pathology</i> , <b>2003</b> , 201, 603-8	9.4	78
342	Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. <i>Cancer Research</i> , <b>2001</b> , 61, 355-62	10.1	78
341	Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. <i>Journal of Pathology</i> , <b>2002</b> , 197, 575-81	9.4	76
340	RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. <i>International Journal of Cancer</i> , <b>2013</b> , 132, 2118-26	7.5	75
339	High Ki67 expression is an independent good prognostic marker in colorectal cancer. <i>Journal of Clinical Pathology</i> , <b>2016</b> , 69, 209-14	3.9	71
338	Mitochondrial mutations drive prostate cancer aggression. <i>Nature Communications</i> , <b>2017</b> , 8, 656	17.4	66
337	Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. <i>Cancers</i> , <b>2019</b> , 11,	6.6	65
336	Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. <i>Human Pathology</i> , <b>2010</b> , 41, 1577-85	3.7	61
335	Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. <i>International Journal of Cancer</i> , <b>2002</b> , 100, 702-5	7.5	61
334	Recipient block TMA technique. <i>Methods in Molecular Biology</i> , <b>2010</b> , 664, 37-44	1.4	60
333	Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. <i>Modern Pathology</i> , <b>2014</b> , 27, 1612-20	9.8	59
332	Tissue microarrays in cancer diagnosis. <i>Expert Review of Molecular Diagnostics</i> , <b>2003</b> , 3, 421-30	3.8	59
331	Comparative genomic hybridization in pineal parenchymal tumors. <i>Genes Chromosomes and Cancer</i> , <b>2001</b> , 30, 99-104	5	59

330	Gene amplification in ductal carcinoma in situ of the breast. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 123, 757-65	4.4	58
329	Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. <i>EMBO Reports</i> , <b>2016</b> , 17, 1609-1623	6.5	58
328	Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. <i>Apmis</i> , <b>2012</b> , 120, 901-8	3.4	57
327	Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2011</b> , 459, 193-200	5.1	57
326	Marked heterogeneity of ERG expression in large primary prostate cancers. <i>Modern Pathology</i> , <b>2013</b> , 26, 106-16	9.8	56
325	Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. <i>PLoS ONE</i> , <b>2013</b> , 8, e54873	3.7	56
324	Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 7838-42	12.9	55
323	KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 1997-2004	8.7	52
322	Immunohistochemical analysis of tissue microarrays. <i>Methods in Molecular Biology</i> , <b>2010</b> , 664, 113-26	1.4	52
321	MMSET is highly expressed and associated with aggressiveness in neuroblastoma. <i>Cancer Research</i> , <b>2011</b> , 71, 4226-35	10.1	51
320	Predominance of high-grade pathway in breast cancer development of Middle East women. <i>Modern Pathology</i> , <b>2005</b> , 18, 891-7	9.8	51
319	Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. <i>Modern Pathology</i> , <b>2007</b> , 20, 192-8	9.8	49
318	Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. <i>Histopathology</i> , <b>2000</b> , 37, 411-23	7.3	49
317	TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. <i>European Urology</i> , <b>2014</b> , 66, 978-81	10.2	48
316	Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 2323-33	5.8	48
315	Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2003</b> , 443, 741-4	5.1	48
314	MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 920-8	7.5	47
313	Proteomic profiling of mammary carcinomas identifies C7orf24, a gamma-glutamyl cyclotransferase, as a potential cancer biomarker. <i>Journal of Proteome Research</i> , <b>2010</b> , 9, 3941-53	5.6	46

312	βII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. <i>American Journal of Pathology</i> , <b>2014</b> , 184, 609-17	5.8	44
311	Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 199-202	8.9	44
310	Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. <i>Cancer</i> , <b>2012</b> , 118, 1268-75	6.4	43
309	Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. <i>Neoplasia</i> , <b>2017</b> , 19, 707-715	6.4	43
308	Tissue microarrays. <i>Methods in Molecular Medicine</i> , <b>2005</b> , 114, 257-68		43
307	The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ER-negative breast cancer. <i>Oncogene</i> , <b>2017</b> , 36, 4124-4134	9.2	41
306	Role of TP53 mutations in vulvar carcinomas. <i>International Journal of Gynecological Pathology</i> , <b>2011</b> , 30, 497-504	3.2	41
305	Reply to ESR1 gene amplification in breast cancer: a common phenomenon? <i>Nature Genetics</i> , <b>2008</b> , 40, 810-812	36.3	41
304	The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability. <i>Molecular Oncology</i> , <b>2008</b> , 1, 431-9	7.9	41
303	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. <i>European Urology</i> , <b>2018</b> , 74, 376-386	10.2	40
302	High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. <i>Molecular Oncology</i> , <b>2013</b> , 7, 1001-11	7.9	40
301	High mitochondria content is associated with prostate cancer disease progression. <i>Molecular Cancer</i> , <b>2013</b> , 12, 145	42.1	39
300	Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. <i>Carcinogenesis</i> , <b>2015</b> , 36, 1333-40	4.6	37
299	Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer. <i>Scientific Reports</i> , <b>2018</b> , 8, 3947	4.9	37
298	Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 1848-58	8.7	37
297	CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. <i>Clinical Oral Investigations</i> , <b>2014</b> , 18, 269-76	4.2	37
296	Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. <i>Molecular and Cellular Proteomics</i> , <b>2010</b> , 9, 161-77	7.6	37
295	Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. <i>Modern Pathology</i> , <b>2012</b> , 25, 1566-73	9.8	37

294	E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. <i>Oncogene</i> , <b>2006</b> , 25, 6538-43	9.2	37
293	Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3471-9	12.9	36
292	PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. <i>Oncotarget</i> , <b>2017</b> , 8, 65566-65576	3.3	35
291	SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. <i>Prostate</i> , <b>2013</b> , 73, 1690-8	4.2	34
290	Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 137, 745-53	4.4	34
289	Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation. <i>Cancer Research</i> , <b>2012</b> , 72, 626-35	10.1	34
288	Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. <i>BMC Cancer</i> , <b>2010</b> , 10, 295	4.8	34
287	High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 852-61	7.5	33
286	Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2354-63	7.5	33
285	High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2331-41	12.9	33
284	Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 8377-87	3.3	33
283	THSD7A expression in human cancer. <i>Genes Chromosomes and Cancer</i> , <b>2017</b> , 56, 314-327	5	32
282	Prevalence of $\beta$ -tubulin (TUBB3) expression in human normal tissues and cancers. <i>Tumor Biology</i> , <b>2017</b> , 39, 1010428317712166	2.9	32
281	Random forest-based modelling to detect biomarkers for prostate cancer progression. <i>Clinical Epigenetics</i> , <b>2019</b> , 11, 148	7.7	32
280	Reprogramming of the ERG and ERG target gene landscape triggers tamoxifen resistance in breast cancer. <i>Cancer Research</i> , <b>2015</b> , 75, 720-31	10.1	32
279	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. <i>European Urology</i> , <b>2018</b> , 73, 674-683	10.2	32
278	Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. <i>International Journal of Cancer</i> , <b>2013</b> , 132, 1333-40	7.5	32
277	Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. <i>Modern Pathology</i> , <b>2013</b> , 26, 733-42	9.8	32



276	Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. <i>Disease Markers</i> , <b>2019</b> , 2019, 5160565	3.2	31
275	Marked gene transcript level alterations occur early during radical prostatectomy. <i>European Urology</i> , <b>2008</b> , 53, 333-44	10.2	31
274	Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. <i>Journal of Pathology</i> , <b>2002</b> , 198, 115-20	9.4	31
273	Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer. <i>Human Pathology</i> , <b>2010</b> , 41, 358-65	3.7	30
272	Deletion of 8p is an independent prognostic parameter in prostate cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 379-392	3.3	30
271	Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer. <i>Carcinogenesis</i> , <b>2017</b> , 38, 19-27	4.6	29
270	The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer. <i>Molecular Cancer Research</i> , <b>2014</b> , 12, 670-80	6.6	29
269	The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 1399-407	7.5	29
268	Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. <i>Journal of Pathology</i> , <b>2008</b> , 216, 151-7	9.4	29
267	Tissue microarray (TMA) applications: implications for molecular medicine. <i>Expert Reviews in Molecular Medicine</i> , <b>2003</b> , 5, 1-12	6.7	29
266	High-throughput tissue microarray analysis of CMYC amplification in urinary bladder cancer. <i>International Journal of Cancer</i> , <b>2005</b> , 117, 952-6	7.5	29
265	Cyclin D1 gene amplification is highly homogeneous in breast cancer. <i>Breast Cancer</i> , <b>2016</b> , 23, 111-119	3.4	28
264	The relationship between annual hospital volume of trauma patients and in-hospital mortality in New York State. <i>Journal of Trauma</i> , <b>2011</b> , 71, 339-45; discussion 345-6		28
263	Y chromosome loss is a frequent early event in urothelial bladder cancer. <i>Pathology</i> , <b>2010</b> , 42, 356-9	1.6	28
262	AMACR expression in colorectal cancer is associated with left-sided tumor localization. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2008</b> , 453, 243-8	5.1	28
261	Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 27966-79	3.3	28
260	High levels of class III $\beta$ -tubulin expression are associated with aggressive tumor features in breast cancer. <i>Oncology Letters</i> , <b>2016</b> , 11, 1987-1994	2.6	28
259	The prognostic value of SUMO1/Sentrin specific peptidase 1 (SEN1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. <i>BMC Cancer</i> , <b>2015</b> , 15, 538	4.8	27

258	Partial PTEN deletion is linked to poor prognosis in breast cancer. <i>BMC Cancer</i> , <b>2015</b> , 15, 963	4.8	27
257	Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome. <i>Modern Pathology</i> , <b>2010</b> , 23, 603-10	9.8	27
256	MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype. <i>Anticancer Research</i> , <b>2014</b> , 34, 2255-61	2.3	27
255	IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. <i>Oncology Reports</i> , <b>2018</b> , 39, 3-12	3.5	26
254	HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. <i>Oncotarget</i> , <b>2015</b> , 6, 12822-34	3.3	26
253	Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene. <i>Prostate</i> , <b>2012</b> , 72, 991-7	4.2	26
252	Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. <i>Histopathology</i> , <b>2010</b> , 57, 418-26	7.3	26
251	Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease. <i>Human Pathology</i> , <b>2009</b> , 40, 166-73	3.7	26
250	Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. <i>Journal of Clinical Pathology</i> , <b>2013</b> , 66, 563-8	3.9	25
249	Predictive molecular pathology. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 1995-6	59.2	25
248	Immunohistochemical and FISH analysis of EGFR and its prognostic value in patients with oral squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , <b>2014</b> , 43, 205-10	3.3	24
247	Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128525	3.7	24
246	High nuclear karyopherin $\beta$ expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. <i>Modern Pathology</i> , <b>2014</b> , 27, 96-106	9.8	24
245	MALDI imaging-based identification of prognostically relevant signals in bladder cancer using large-scale tissue microarrays. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 1225-33 <sup>2.8</sup>	2.8	24
244	EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome. <i>Journal of Clinical Pathology</i> , <b>2012</b> , 65, 133-9	3.9	24
243	p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 81322-81331	3.3	24
242	High intratumoral FOXP3+ T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2015</b> , 8, 8227-35	1.4	24
241	Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 2056	4.9	23

240	Aberrant presentation of HPA-reactive carbohydrates implies Selectin-independent metastasis formation in human prostate cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1791-802	12.9	23
239	Loss of protein expression and recurrent DNA hypermethylation of the GNG7 gene in squamous cell carcinoma of the head and neck. <i>Journal of Applied Genetics</i> , <b>2012</b> , 53, 167-74	2.5	23
238	Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2006</b> , 1766, 42-52	11.2	23
237	Deletion of 18q is a strong and independent prognostic feature in prostate cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 86339-86349	3.3	23
236	Tissue microarrays. <i>Methods in Molecular Biology</i> , <b>2010</b> , 576, 49-60	1.4	23
235	Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 139	17.4	22
234	13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. <i>Genes Chromosomes and Cancer</i> , <b>2018</b> , 57, 504-512	5	22
233	Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR. <i>International Journal of Oncology</i> , <b>2014</b> , 44, 609-15	4.4	22
232	Immunohistochemical analysis of p16 expression, HPV infection and its prognostic utility in oral squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , <b>2013</b> , 42, 676-81	3.3	22
231	Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors. <i>BMC Medical Genetics</i> , <b>2010</b> , 11, 106	2.1	22
230	Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 1199-206	7.5	21
229	Internal standardization of LA-ICP-MS immuno imaging via printing of universal metal spiked inks onto tissue sections. <i>Journal of Analytical Atomic Spectrometry</i> , <b>2016</b> , 31, 801-808	3.7	21
228	The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. <i>International Journal of Oncology</i> , <b>2012</b> , 40, 261-8	4.4	21
227	Molecular cancer phenotype in normal prostate tissue. <i>European Urology</i> , <b>2009</b> , 55, 885-90	10.2	21
226	Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 108923-108935	3.3	21
225	HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. <i>Experimental and Molecular Pathology</i> , <b>2015</b> , 98, 419-26	4.4	20
224	8p deletion is strongly linked to poor prognosis in breast cancer. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 1080-7	4.6	20
223	Immunohistochemically detected IDH1 mutation is rare and mostly heterogeneous in prostate cancer. <i>World Journal of Urology</i> , <b>2018</b> , 36, 877-882	4	20

222	MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer. <i>Cancer Biomarkers</i> , <b>2010</b> , 8, 53-60	3.8	20
221	Microsatellite DNA alterations of gastrointestinal stromal tumors are predictive for outcome. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 5151-7	12.9	20
220	High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. <i>Human Pathology</i> , <b>2006</b> , 37, 453-7	3.7	20
219	Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. <i>Aging</i> , <b>2019</b> , 11, 7796-7804	5.6	20
218	Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues. <i>Disease Markers</i> , <b>2019</b> , 2019, 4928315	3.2	20
217	Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients. <i>BMC Cancer</i> , <b>2016</b> , 16, 641	4.8	19
216	PSMA expression is highly homogenous in primary prostate cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2015</b> , 23, 449-55	1.9	19
215	PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer. <i>Histopathology</i> , <b>2013</b> , 63, 670-7	7.3	19
214	MALDI imaging on large-scale tissue microarrays identifies molecular features associated with tumour phenotype in oesophageal cancer. <i>Histopathology</i> , <b>2013</b> , 63, 455-62	7.3	18
213	Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. <i>Oncology Letters</i> , <b>2013</b> , 6, 1245-1252	2.6	18
212	Tissue microarrays for high-throughput molecular pathology. <i>Annals of Saudi Medicine</i> , <b>2004</b> , 24, 169-74	1.6	18
211	Tissue Microarrays. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1381, 53-65	1.4	18
210	Loss of RNA-binding motif protein 3 expression is associated with right-sided localization and poor prognosis in colorectal cancer. <i>Histopathology</i> , <b>2016</b> , 68, 191-8	7.3	18
209	Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. <i>Prostate</i> , <b>2016</b> , 76, 259-72	4.2	18
208	HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. <i>International Journal of Oncology</i> , <b>2004</b> , 25, 1551-7	1	18
207	MALDI imaging mass spectrometry reveals multiple clinically relevant masses in colorectal cancer using large-scale tissue microarrays. <i>Journal of Mass Spectrometry</i> , <b>2017</b> , 52, 165-173	2.2	17
206	Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence. <i>Human Pathology</i> , <b>2013</b> , 44, 1789-96	3.7	17
205	Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer. <i>Human Pathology</i> , <b>2013</b> , 44, 1524-33	3.7	17

204	No detection of XMRV in blood samples and tissue sections from prostate cancer patients in Northern Europe. <i>PLoS ONE</i> , <b>2011</b> , 6, e25592	3.7	17
203	Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2010</b> , 456, 483-90	5.1	17
202	19q13 amplification is associated with high grade and stage in pancreatic cancer. <i>Genes Chromosomes and Cancer</i> , <b>2010</b> , 49, 569-75	5	17
201	Distinct gene expression profiles: nodal versus extranodal diffuse large B-cell lymphoma. <i>Oncology</i> , <b>2008</b> , 75, 71-80	3.6	17
200	The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. <i>Analytical Cellular Pathology</i> , <b>2006</b> , 28, 223-32	3.4	17
199	BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy. <i>Cancer Letters</i> , <b>2018</b> , 423, 60-70	9.9	16
198	p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. <i>Tumor Biology</i> , <b>2016</b> , 37, 12655-12663	2.9	16
197	Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients. <i>Oncology Reports</i> , <b>2014</b> , 32, 2628-34	3.5	16
196	Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer. <i>Diagnostic Pathology</i> , <b>2015</b> , 10, 125	3	16
195	Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 559-65	3.1	16
194	PPF1A1 and CCND1 are frequently coamplified in breast cancer. <i>Genes Chromosomes and Cancer</i> , <b>2010</b> , 49, 1-8	5	16
193	Tissue microarrays. <i>Methods in Molecular Medicine</i> , <b>2004</b> , 97, 377-89		16
192	Patterns of chromosomal imbalances in muscle invasive bladder cancer. <i>International Journal of Oncology</i> , <b>2000</b> , 17, 1025-9	1	16
191	Diverse expression patterns of the EMT suppressor grainyhead-like 2 (GRHL2) in normal and tumour tissues. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 949-63	7.5	16
190	β-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer. <i>Human Pathology</i> , <b>2017</b> , 61, 210-220	3.7	15
189	Prevalence of CD8 cytotoxic lymphocytes in human neoplasms. <i>Cellular Oncology (Dordrecht)</i> , <b>2020</b> , 43, 421-430	7.2	15
188	Loss of H2Bub1 Expression is Linked to Poor Prognosis in Nodal Negative Colorectal Cancers. <i>Pathology and Oncology Research</i> , <b>2016</b> , 22, 95-102	2.6	15
187	High-Level βGlutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	15

186	PTEN deletion is rare but often homogeneous in gastric cancer. <i>Journal of Clinical Pathology</i> , <b>2012</b> , 65, 693-8	3.9	15
185	Applications of tissue microarray technology. <i>Methods in Molecular Biology</i> , <b>2010</b> , 664, 1-16	1.4	15
184	Identification of a High-Level MET Amplification in CTCs and cTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, e243-e246	8.9	15
183	p53 overexpression is a prognosticator of poor outcome in esophageal cancer. <i>Oncology Letters</i> , <b>2019</b> , 17, 3826-3834	2.6	14
182	High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 37	4.8	14
181	On the evidence for ESR1 amplification in breast cancer. <i>Nature Reviews Cancer</i> , <b>2012</b> , 12, 149	31.3	14
180	Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. <i>Lung Cancer</i> , <b>2013</b> , 79, 221-7	5.9	14
179	Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients. <i>Oncology Letters</i> , <b>2010</b> , 1, 729-732	2.6	14
178	High frequency and strong prognostic relevance of O6-methylguanine DNA methyltransferase silencing in diffuse large B-cell lymphomas from the Middle East. <i>Human Pathology</i> , <b>2006</b> , 37, 742-8	3.7	14
177	Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer. <i>Scientific Reports</i> , <b>2018</b> , 8, 17535	4.9	14
176	Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma. <i>BMC Cancer</i> , <b>2018</b> , 18, 1202-8	4.8	14
175	Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. <i>BMC Cancer</i> , <b>2019</b> , 19, 193	4.8	13
174	MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 3997-4006	3.1	13
173	High homogeneity of MMR deficiency in ovarian cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 156, 669-675	4.9	13
172	Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence. <i>Human Pathology</i> , <b>2016</b> , 48, 102-10	3.7	13
171	Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. <i>Experimental and Molecular Pathology</i> , <b>2013</b> , 95, 227-34	4.4	13
170	Amplification of the PPFIA1 gene region on 11q13 in oral squamous cell carcinomas (OSCC). <i>Journal of Cranio-Maxillo-Facial Surgery</i> , <b>2013</b> , 41, 845-9	3.6	13
169	Role of cyclin D1 amplification and expression in vulvar carcinomas. <i>Human Pathology</i> , <b>2012</b> , 43, 1386-93	3.7	13

168	ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous. <i>PLoS ONE</i> , <b>2013</b> , 8, e84189	3.7	13
167	HER-2/neu analysis in breast cancer bone metastases. <i>Journal of Clinical Pathology</i> , <b>2009</b> , 62, 542-6	3.9	13
166	Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors <b>2004</b> , 25, 641		13
165	FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma. <i>PLoS ONE</i> , <b>2015</b> , 10, e0141867	3.7	13
164	The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2802-11	12.9	13
163	Apurinic/aprimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion. <i>Molecular Carcinogenesis</i> , <b>2017</b> , 56, 2135-2145	5	12
162	PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 612	4.8	12
161	BIRC2 amplification in squamous cell carcinomas of the uterine cervix. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2012</b> , 461, 123-8	5.1	12
160	High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. <i>Experimental and Therapeutic Medicine</i> , <b>2013</b> , 5, 102-106	2.1	12
159	FISH Oracle: a web server for flexible visualization of DNA copy number data in a genomic context. <i>Journal of Clinical Bioinformatics</i> , <b>2011</b> , 1, 20		12
158	Estrogen receptor gene amplification occurs rarely in ovarian cancer. <i>Modern Pathology</i> , <b>2009</b> , 22, 191-6	9.8	12
157	Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. <i>Oncotarget</i> , <b>2019</b> , 10, 5439-5453	3.3	12
156	Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. <i>Neoplasia</i> , <b>2017</b> , 19, 279-287	6.4	11
155	16p13.11 microdeletion uncovers loss-of-function of a MYH11 missense variant in a patient with megacystis-microcolon-intestinal-hypoperistalsis syndrome. <i>Clinical Genetics</i> , <b>2019</b> , 96, 85-90	4	11
154	IL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans. <i>Gastroenterology</i> , <b>2020</b> , 159, 1417-1430.e3	13.3	11
153	Epstein-Barr virus infection is not the sole cause of high prevalence for Hodgkin's lymphoma in Saudi Arabia. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 707-13	1.9	11
152	Expression and amplification of therapeutic target genes in retinoblastoma. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2005</b> , 243, 156-62	3.8	11
151	Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes. <i>Oncotarget</i> , <b>2020</b> , 11, 237-249	3.3	11

150	Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma. <i>Oncotarget</i> , <b>2020</b> , 11, 1007-1016	3.3	11
149	High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer. <i>International Journal of Colorectal Disease</i> , <b>2020</b> , 35, 259-268	3	11
148	TIP5 primes prostate luminal cells for the oncogenic transformation mediated by -loss. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 3637-3647	11.5	11
147	Upregulation of centromere protein F is linked to aggressive prostate cancers. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 5491-5504	3.6	11
146	FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy. <i>Carcinogenesis</i> , <b>2017</b> , 38, 1180-1187	4.6	10
145	βII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. <i>World Journal of Urology</i> , <b>2015</b> , 33, 1561-9	4	10
144	EZH2 overexpression in head and neck cancer is related to lymph node metastasis. <i>Journal of Oral Pathology and Medicine</i> , <b>2018</b> , 47, 240-245	3.3	10
143	Quantification of telomere features in tumor tissue sections by an automated 3D imaging-based workflow. <i>Methods</i> , <b>2017</b> , 114, 60-73	4.6	10
142	HER-2 amplification is highly homogenous in gastric cancer. <i>Human Pathology</i> , <b>2010</b> , 41, 305-306	3.7	10
141	Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer. <i>Pathology</i> , <b>2012</b> , 44, 448-52	1.6	10
140	NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer. <i>Prostate</i> , <b>2014</b> , 74, 1012-22	4.2	9
139	Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer. <i>International Journal of Oncology</i> , <b>2015</b> , 46, 1637-42	4.4	9
138	High homogeneity of mismatch repair deficiency in advanced prostate cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 476, 745-752	5.1	9
137	Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	9
136	Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 531.e19-531.e25	2.8	9
135	Colorectal carcinoma from Saudi Arabia. Analysis of MLH-1, MSH-2 and p53 genes by immunohistochemistry and tissue microarray analysis. <i>Journal of King Abdulaziz University, Islamic Economics</i> , <b>2006</b> , 27, 323-8	1.1	9
134	MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 488-495	2.8	8
133	A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. <i>Molecular Carcinogenesis</i> , <b>2019</b> , 58, 2306-2315	5.1	8



132	Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. <i>Gynecologic Oncology</i> , <b>2014</b> , 134, 599-606	4.9	8
131	High-level $\beta$ -tubulin overexpression occurs in most head and neck cancers but is unrelated to clinical outcome. <i>Journal of Oral Pathology and Medicine</i> , <b>2017</b> , 46, 986-990	3.3	8
130	High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer. <i>PLoS ONE</i> , <b>2015</b> , 10, e0134614	3.7	8
129	Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer. <i>Molecular Oncology</i> , <b>2020</b> , 14, 129-138	7.9	8
128	High B7-H3 expression is linked to increased risk of prostate cancer progression. <i>Pathology International</i> , <b>2020</b> , 70, 733-742	1.8	8
127	Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. <i>Disease Markers</i> , <b>2019</b> , 2019, 2532518	3.18	7
126	Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers. <i>Human Pathology</i> , <b>2015</b> , 46, 514-23	3.7	7
125	Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas. <i>Endocrine Pathology</i> , <b>2020</b> , 31, 182-189	4.2	7
124	Y chromosome losses are exceedingly rare in prostate cancer and unrelated to patient age. <i>Prostate</i> , <b>2012</b> , 72, 898-903	4.2	7
123	Immunoexpression analysis and prognostic value of BLCAP in breast cancer. <i>PLoS ONE</i> , <b>2012</b> , 7, e45967	3.7	7
122	Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer. <i>Aging</i> , <b>2019</b> , 11, 7859-7879	5.6	7
121	Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2015</b> , 8, 7009-15	1.4	7
120	Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay. <i>Cells</i> , <b>2020</b> , 9,	7.9	7
119	High expression of class III $\beta$ -tubulin in upper gastrointestinal cancer types. <i>Oncology Letters</i> , <b>2018</b> , 16, 7139-7145	2.6	7
118	High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer. <i>Prostate</i> , <b>2017</b> , 77, 1528-1538	4.2	6
117	Expression of the immune checkpoint receptor TIGIT in seminoma. <i>Oncology Letters</i> , <b>2019</b> , 18, 1497-1502	2.6	6
116	P53 immunohistochemical expression does not correlate with clinical features in 207 carcinomas of the oral cavity and in the head and neck region. <i>Clinical Oral Investigations</i> , <b>2014</b> , 18, 211-7	4.2	6
115	Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays. <i>Pathology and Oncology Research</i> , <b>2015</b> , 21, 1183-9	2.6	6

114	Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. <i>Oncology Reports</i> , <b>2015</b> , 34, 1211-20	3.5	6
113	High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2013</b> , 16, 159-64	6.2	6
112	Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 3897-904	3.3	6
111	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. <i>World Journal of Urology</i> , <b>2020</b> , 38, 2185-2196	4	6
110	Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome. <i>BMC Cancer</i> , <b>2018</b> , 18, 1106	4.8	6
109	Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers. <i>Scientific Reports</i> , <b>2020</b> , 10, 8916	4.9	5
108	Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer. <i>Prostate</i> , <b>2020</b> , 80, 1097-1107	4.2	5
107	Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. <i>BMC Cancer</i> , <b>2017</b> , 17, 504	4.8	5
106	Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer. <i>Molecular Medicine Reports</i> , <b>2016</b> , 14, 1443-50	2.9	5
105	Patterns of ALK expression in different human cancer types. <i>Journal of Clinical Pathology</i> , <b>2014</b> , 67, 477-81	3.1	5
104	FISH Oracle 2: a web server for integrative visualization of genomic data in cancer research. <i>Journal of Clinical Bioinformatics</i> , <b>2014</b> , 4, 5		5
103	Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness. <i>Biochemical and Biophysical Research Communications</i> , <b>2005</b> , 329, 318-23	3.4	5
102	High throughput tissue microarray analysis of FHIT expression in diffuse large cell B-cell lymphoma from Saudi Arabia. <i>Modern Pathology</i> , <b>2006</b> , 19, 1124-9	9.8	5
101	Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer. <i>Medical Molecular Morphology</i> , <b>2021</b> , 54, 156-163	2.3	5
100	8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 43.e13-43.e20	2.8	5
99	Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. <i>Molecular Medicine</i> , <b>2021</b> , 27, 16	6.2	5
98	Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer. <i>Experimental and Molecular Pathology</i> , <b>2018</b> , 105, 50-56	4.4	5
97	Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma. <i>Childs Nervous System</i> , <b>2016</b> , 32, 281-90	1.7	4

96	The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer. <i>Tumor Biology</i> , <b>2019</b> , 41, 1010428318824815	2.9	4
95	Reduced membranous MET expression is linked to bladder cancer progression. <i>Cancer Genetics</i> , <b>2014</b> , 207, 147-52	2.3	4
94	Tissue microarrays for early target evaluation. <i>Drug Discovery Today: Technologies</i> , <b>2004</b> , 1, 41-8	7.1	4
93	Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients. <i>Cancer Medicine</i> , <b>2020</b> , 9, 1409-1418	4.8	4
92	High RSF1 protein expression is an independent prognostic feature in prostate cancer. <i>Acta Oncologica</i> , <b>2020</b> , 59, 268-273	3.2	4
91	Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions. <i>Pathology and Oncology Research</i> , <b>2020</b> , 26, 2709-2722	2.6	4
90	Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 137, 93-107	7.5	4
89	Prognostic role of proliferating CD8 cytotoxic T cells in human cancers. <i>Cellular Oncology (Dordrecht)</i> , <b>2021</b> , 44, 793-803	7.2	4
88	Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. <i>Pathology International</i> , <b>2020</b> , 70, 441-451	1.8	4
87	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. <i>World Journal of Urology</i> , <b>2021</b> , 39, 481-490	4	4
86	p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. <i>Biomarker Research</i> , <b>2021</b> , 9, 7	8	4
85	Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors. <i>Human Pathology</i> , <b>2021</b> , 115, 19-36	3.7	4
84	Hyperparameter optimization for image analysis: application to prostate tissue images and live cell data of virus-infected cells. <i>International Journal of Computer Assisted Radiology and Surgery</i> , <b>2019</b> , 14, 1847-1857	3.9	3
83	VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 8591-606	6.3	3
82	Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10501-10501	2.2	3
81	Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 31494-31508	3.3	3
80	Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy. <i>Oncotarget</i> , <b>2019</b> , 10, 4973-4986	3.3	3
79	Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion. <i>Oncotarget</i> , <b>2019</b> , 10, 7096-7111	3.3	3

78	Upregulation of SPDEF is associated with poor prognosis in prostate cancer. <i>Oncology Letters</i> , <b>2019</b> , 18, 5107-5118	2.6	3
77	Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. <i>BioMed Research International</i> , <b>2020</b> , 2020, 5845374	3	3
76	Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. <i>Clinical and Experimental Metastasis</i> , <b>2020</b> , 37, 649-656	4.7	3
75	Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer. <i>BMC Cancer</i> , <b>2020</b> , 20, 1220	4.8	3
74	Prevalence of proliferating CD8 cells in normal lymphatic tissues, inflammation and cancer. <i>Aging</i> , <b>2021</b> , 13, 14590-14603	5.6	3
73	E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors. <i>Biomarker Research</i> , <b>2021</b> , 9, 44	8	3
72	5q21 deletion is often heterogeneous in prostate cancer. <i>Genes Chromosomes and Cancer</i> , <b>2019</b> , 58, 509-515	5	3
71	A non-diploid DNA status is linked to poor prognosis in renal cell cancer. <i>World Journal of Urology</i> , <b>2021</b> , 39, 829-837	4	3
70	High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases. <i>Oncology Letters</i> , <b>2018</b> , 16, 6238-6244	2.6	3
69	Immunohistochemically detectable thyroglobulin expression in extrathyroidal cancer is 100% specific for thyroidal tumor origin. <i>Annals of Diagnostic Pathology</i> , <b>2021</b> , 54, 151793	2.2	3
68	Chromosomal aberrations associated with invasion in papillary superficial bladder cancer <b>1998</b> , 185, 345		3
67	Angiotensin-Converting Enzyme 2 Protein Is Overexpressed in a Wide Range of Human Tumour Types: A Systematic Tissue Microarray Study on >15,000 Tumours.. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	3
66	High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens. <i>BJU International</i> , <b>2017</b> , 120, 365-376	5.6	2
65	SNW1 is a prognostic biomarker in prostate cancer. <i>Diagnostic Pathology</i> , <b>2019</b> , 14, 33	3	2
64	Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer. <i>Disease Markers</i> , <b>2020</b> , 2020, 7050146	3.2	2
63	Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma. <i>World Journal of Surgical Oncology</i> , <b>2020</b> , 18, 128	3.4	2
62	Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. <i>Molecular Medicine</i> , <b>2020</b> , 26, 24	6.2	2
61	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 575-583	7.5	2

60	High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer. <i>Pathology</i> , <b>2020</b> , 52, 421-430	1.6	2
59	Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 605.e1-605.e8	2.8	2
58	Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. <i>Neoplasia</i> , <b>2019</b> , 21, 872-881	6.4	2
57	Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer. <i>Microarrays (Basel, Switzerland)</i> , <b>2014</b> , 3, 137-58		2
56	HER2 amplification in squamous cell carcinomas of the vulva. <i>Histopathology</i> , <b>2013</b> , 62, 965-7	7.3	2
55	Abstract 696: Patterns of TIGIT expression in normal lymphatic tissue, inflammation and cancer <b>2018</b> ,		2
54	A nuclear shift of GSK3 $\beta$ protein is an independent prognostic factor in prostate cancer. <i>Oncotarget</i> , <b>2019</b> , 10, 1729-1744	3.3	2
53	DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples. <i>Pathology Research and Practice</i> , <b>2021</b> , 228, 153663	3.4	2
52	Carboxypeptidase A1 (CPA1) Immunohistochemistry Is Highly Sensitive and Specific for Acinar Cell Carcinoma (ACC) of the Pancreas. <i>American Journal of Surgical Pathology</i> , <b>2022</b> , 46, 97-104	6.7	2
51	Napsin A Expression in Human Tumors and Normal Tissues. <i>Pathology and Oncology Research</i> , <b>2021</b> , 27, 613099	2.6	2
50	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. <i>International Urology and Nephrology</i> , <b>2021</b> , 53, 2493-2503	2.3	2
49	Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. <i>Prostate</i> , <b>2019</b> , 79, 302-311	4.2	2
48	Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 748-758	7.5	2
47	MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10 399 Tissue Samples. <i>Technology in Cancer Research and Treatment</i> , <b>2021</b> , 20, 15330338211043328	2.7	2
46	Y-chromosome loss is frequent in male renal tumors. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 209	3.2	2
45	Deletion of 3p13 is a late event linked to progression of : fusion prostate cancer. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 5909-5917	3.6	2
44	CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo. <i>Cancer Gene Therapy</i> , <b>2021</b> ,	5.4	2
43	Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes <b>1999</b> , 189, 521		2

42	Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of deleted prostate cancers. <i>Cancer Biology and Medicine</i> , <b>2019</b> , 16, 319-330	5.2	1
41	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 477, 625-636	5.1	1
40	CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer. <i>Clinical Oral Investigations</i> , <b>2017</b> , 21, 1503-1508	4.2	1
39	HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis - reply. <i>Human Pathology</i> , <b>2011</b> , 42, 910-911	3.7	1
38	High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer <b>2005</b> , 27, 385		1
37	Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma.. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	1
36	Random forest-based modelling to detect biomarkers for prostate cancer progression		1
35	Ectopic Expression of Hematopoietic SHIP1 in Human Colorectal Cancer. <i>Biomedicines</i> , <b>2020</b> , 8,	4.8	1
34	Mismatch repair deficiency occurs very rarely in seminomas. <i>Translational Andrology and Urology</i> , <b>2021</b> , 10, 1048-1055	2.3	1
33	High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer. <i>Acta Oncologica</i> , <b>2021</b> , 60, 1210-1217	3.2	1
32	Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. <i>Cancer Biology and Medicine</i> , <b>2021</b> , 18, 245-255	5.2	1
31	MUC5AC expression is linked to mucinous/endometrioid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer. <i>Pathology Research and Practice</i> , <b>2021</b> , 224, 153533	3.4	1
30	Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness. <i>Cancer Investigation</i> , <b>2021</b> , 39, 711-720	2.1	1
29	High mitochondrial content is associated with breast cancer aggressiveness. <i>Molecular and Clinical Oncology</i> , <b>2021</b> , 15, 203	1.6	1
28	DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness. <i>PeerJ</i> , <b>2021</b> , 9, e11905	3.1	1
27	Pattern of placental alkaline phosphatase (PLAP) expression in human tumors: a tissue microarray study on 12,381 tumors. <i>Journal of Pathology: Clinical Research</i> , <b>2021</b> , 7, 577-589	5.3	1
26	Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report. <i>Oncology Research and Treatment</i> , <b>2021</b> , 44, 495-502	2.8	1
25	Chromosomal aberrations associated with invasion in papillary superficial bladder cancer <b>1998</b> , 185, 345		1

24	Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways <b>1999</b> , 187, 396		1
23	Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.. <i>Pathobiology</i> , <b>2022</b> , 1-14	3.6	1
22	High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer. <i>BMC Cancer</i> , <b>2019</b> , 19, 944	4.8	0
21	Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 2879-2884	4.9	0
20	Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2021</b> , 29, e29-e38	1.9	0
19	Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets. <i>Molecular Oncology</i> , <b>2021</b> , 15, 1956-1969	7.9	0
18	Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2021</b> , 1	5.1	0
17	Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers.. <i>Experimental and Molecular Pathology</i> , <b>2022</b> , 104762	4.4	0
16	βII-tubulin overexpression is linked to left-sided tumor localization and nuclear βcatenin expression in colorectal cancer. <i>Cancer Treatment Communications</i> , <b>2015</b> , 4, 96-102		
15	Internationales Krebsgenomkonsortium (ICGC). <i>Medizinische Genetik</i> , <b>2016</b> , 28, 416-423	0.5	
14	Tissue Microarrays for Miniaturized High-Throughput Molecular Profiling of Tumors <b>2005</b> , 345-360		
13	Chromosomal Aberrations Associated With Invasion in Papillary Superficial Bladder Cancer. <i>Journal of Urology</i> , <b>1999</b> , 162, 621-621	2.5	
12	P02.06 Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence <b>2021</b> , 9, A9.3-A10		
11	P02.03 Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human cancers <b>2021</b> , 9, A8.2-A9		
10	6q deletion is frequent but unrelated to patient prognosis in breast cancer. <i>Breast Cancer</i> , <b>2021</b> , 1	3.4	
9	Prognostic Molecular Features in Diffuse Large B-Cell Lymphoma from Saudi Arabia.. <i>Blood</i> , <b>2004</b> , 104, 4609-4609	2.2	
8	Epstein-Barr Virus Infection Is Not the Sole Cause of High Prevalence for Hodgkin's Lymphoma in Saudi Arabia.. <i>Blood</i> , <b>2004</b> , 104, 3120-3120	2.2	
7	Tissue Microarrays in Pathology <b>2004</b> , 1271-1276		

- 6 Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence. *American Journal of Clinical Pathology*, **2021**, 156, S137-S138<sup>19</sup>
- 5 The combination of DNA ploidy status and PTEN/6q15 deletions to provide strong and independent prognostic information in prostate cancer.. *Journal of Clinical Oncology*, **2015**, 33, 5027-5027<sup>22</sup>
- 4 Association of nuclear accumulation of p53 with ERG fusion and poor prognosis in prostate cancer.. *Journal of Clinical Oncology*, **2012**, 30, 124-124 2.2
- 3 P03.01 Prevalence of CD112R+immune cells in normal lymphatic tissues, inflammation and the cancer microenvironment **2020**, 8, A22.1-A22
- 2 P03.10 Prevalence and prognostic role of FoxP3+regulatory T lymphocytes in cancer. A tissue microarray study on >20000 cancers **2020**, 8, A26.1-A26
- 1 P03.06 Pattern of Ki67+expanding CD8+cytotoxic T cells in healthy tissues, inflammation and the cancer microenvironment **2020**, 8, A24.2-A25